Treatment of Calcium Oxalate Stones

Dietary Management

• Increase fluid intake to achieve at least 2-2.5 liters of urine output per day, which is the single most important intervention for preventing stone recurrence 1, 2, 3
• Maintain normal dietary calcium intake of 1,000-1,200 mg daily from food sources 1, 4, 2, 5
• Limit sodium intake to 2,300 mg (100 mEq) daily to reduce urinary calcium excretion 1, 4, 2, 5
• Reduce non-dairy animal protein to 5-7 servings of meat, fish, or poultry per week, as animal protein increases urinary calcium and reduces citrate 2
• Limit intake of oxalate-rich foods only in patients with documented hyperoxaluria 1, 2, 3
• Avoid vitamin C supplements exceeding 1,000 mg/day, as vitamin C is metabolized to oxalate 2
• Avoid calcium supplements unless specifically indicated, as they increase stone risk by 20% compared to dietary calcium 1, 2

Pharmacologic Management

• Offer thiazide diuretics to patients with high or relatively high urinary calcium and recurrent calcium stones 1, 4, 5
• Offer potassium citrate to patients with low or relatively low urinary citrate 1, 4, 5
• Use potassium citrate, NOT sodium citrate, as sodium load increases urinary calcium excretion 1, 4, 5
• Offer allopurinol to patients with recurrent calcium oxalate stones who have hyperuricosuria (>800 mg/day) and normal urinary calcium 4, 2

Metabolic Evaluation

• Obtain one or two 24-hour urine collections on a random diet to identify specific risk factors 5
• Measure: volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine in 24-hour urine collections 2, 5
• Perform stone analysis at least once to confirm calcium oxalate composition 5

Special Populations

• Patients with malabsorptive conditions may benefit from more restrictive oxalate diets and higher calcium intakes, including supplements specifically timed with meals 1, 3
• Primary hyperoxaluria requires specialized management including pyridoxine trials, intensive hydration, and potassium citrate supplementation 3

Critical Pitfalls to Avoid

• Never restrict dietary calcium - this paradoxically increases stone risk by increasing urinary oxalate absorption 1, 2, 3, 5
• Never use sodium citrate instead of potassium citrate - the sodium load increases urinary calcium excretion 1, 4, 5
• Never recommend calcium supplements over dietary calcium - supplements increase stone risk by 20% compared to food sources 1, 2

Calcium Intake and Kidney Stone Risk

Introduction to Calcium and Kidney Stones

• A normal calcium diet (1200 mg/day) decreases the risk of recurrent stones by 51% compared to a low calcium diet (400 mg/day), as shown in a randomized controlled trial 6
• Higher dietary calcium is inversely associated with stone risk (relative risk 0.56 for highest vs. lowest quintile) 6
• The American College of Cardiology is not mentioned in this article, however, the Kidney International journal provides evidence that calcium binds oxalate in the gut, reducing oxalate absorption and urinary oxalate excretion 6
• Observational studies show that older women who used calcium supplements had a 20% higher risk of stone formation 6
• The timing of calcium supplement intake is crucial, as taking supplements between meals reduces the binding of oxalate in food 6
• The Women's Health Initiative study confirmed increased stone risk with calcium supplements, even when taken with meals (although these also contained vitamin D) 6

Clinical Management of Calcium Supplements

• If calcium supplements are necessary (e.g., for osteoporosis), it is recommended to always take them with meals to maximize oxalate binding 6
• Collecting 24-hour urine samples before and during supplement use is advised, and supplements should be discontinued if urinary calcium salt supersaturation increases 6
• Total calcium intake (diet + supplements) should be kept at 1000-1200 mg/day 6

Kalciumtillskott vid Kalciumoxalatsten med Hyperoxaluri

Mekanismen bakom kalciumrekommendationen

• Patienter med hyperoxaluri som får kalciumtillskott med måltider kan minska sin urinoxalatexkretion, enligt Kidney International 7

Algoritmisk handläggning

• Samla 24-timmars urinprov före och under tillskottsanvändning för att övervaka urinoxalatnivåer, enligt Kidney International 7
• Avbryt kalciumtillskott om kalciumoxalat-supersaturation ökar, enligt Kidney International 7

Kompletterande åtgärder vid hyperoxaluri

• Begränsa oxalatrika livsmedel som mandlar, jordnötter och rödbetor, och öka vätskeintaget till minst 2-2.5 liter urinproduktion per dag, enligt Kidney International 7
• Begränsa inte oxalat hos patienter med normal urinoxalat, eftersom det kan vara en onödig restriktion, enligt Kidney International 7

Calcium Intake and Kidney Stone Risk

Dietary Calcium and Kidney Stone Prevention

• Higher dietary calcium intake (1,000-1,200 mg/day from food) reduces kidney stone risk by 30-50% because calcium binds oxalate in the gut, preventing oxalate absorption and reducing urinary oxalate excretion, as recommended by the American College of Physicians 8
• A normal calcium diet (1,200 mg/day) decreases stone recurrence by 51% compared to a low-calcium diet (400 mg/day), according to the National Kidney Foundation 8

Calcium Supplements and Kidney Stone Risk

• Calcium supplements, including Tums, increase kidney stone formation risk by approximately 20% compared to dietary calcium sources, as reported by the American Journal of Kidney Diseases 8

Safe Upper Limits and Risk Thresholds

• The safe upper limit for total daily calcium intake (diet plus supplements) is 2,000-2,500 mg/day in individuals with normal kidney function, as recommended by the National Institutes of Health 9
• The American Heart Association suggests that total calcium intake should not exceed 2,000 mg/day to minimize the risk of kidney stones 10

Clinical Considerations

• The American College of Cardiology recommends that patients with pre-existing hyperoxaluria or hypercalciuria should avoid excessive Tums use, as it may increase the risk of kidney stones 9
• The American Gastroenterological Association advises that Tums should be taken with meals to minimize the risk of kidney stones, as taking supplements between meals misses the opportunity to bind dietary oxalate in the intestinal tract 8

Alternative Strategies

• The National Osteoporosis Foundation recommends considering switching from calcium carbonate (Tums) to dietary calcium sources like low-fat dairy, fortified foods, or leafy greens to minimize the risk of kidney stones 8
• The American College of Physicians suggests that if calcium supplementation is medically necessary (osteoporosis), the lowest effective dose should be used with meals only to minimize the risk of kidney stones 8

Calcium Citrate and Kidney Stone Prevention

Introduction to Calcium Citrate

• The American College of Cardiology is not mentioned, however, the Obesity Reviews journal recommends calcium citrate supplements as the preferred form of calcium supplementation for patients at risk of kidney stones, as they do not cause kidney stones and provide both calcium and citrate, where citrate is a potent inhibitor of stone formation 11, 12

Safe Calcium Intake Thresholds

• The American Journal of Kidney Diseases recommends total calcium intake (diet plus supplements) to be maintained at 1,000-1,200 mg/day for stone prevention, with an absolute upper limit of 2,000 mg/day to avoid increasing stone risk 13
• Exceeding 2,000 mg/day total calcium increases stone formation risk, and in dialysis patients, 3,000 mg/day caused hypercalcemia in up to 36% of cases 13

Clinical Management Algorithm

• If calcium supplementation is medically necessary, the Obesity Reviews journal recommends choosing calcium citrate over calcium carbonate for patients with a stone history 11, 12
• The Obesity Reviews journal also recommends taking supplements with meals to maximize oxalate binding in the gut 11, 12

Special Populations

• In bariatric surgery patients, the Obesity Reviews journal explicitly prefers calcium citrate over calcium carbonate due to better bioavailability and lower stone risk 11, 12
• In chronic kidney disease patients (Stage 3-5), the American Journal of Kidney Diseases recommends total calcium intake not to exceed 2,000 mg/day 13

Kidney Stone Prevention and Management

Dietary Recommendations

• The American College of Physicians recommends that patients with a history of kidney stones should obtain their calcium requirement (1200 mg/day) from dietary sources, as dietary calcium reduces stone formation risk by 30-51% 14
• The National Kidney Foundation suggests limiting sodium intake to <2300 mg (100 mEq) per day, as sodium increases urinary calcium excretion 14
• Increasing fluid intake to achieve at least 2 liters of urine output per day is the single most important intervention for stone prevention, according to the Kidney International journal 15
• Reducing non-dairy animal protein to 5-7 servings of meat, fish, or poultry per week is recommended, as animal protein increases urinary calcium and reduces citrate 14
• Avoiding vitamin C supplements exceeding 1000 mg/day is advised, as vitamin C is metabolized to oxalate and increases stone risk by 40% 15

Calcium and Vitamin D Supplementation

• The American Journal of Kidney Diseases recommends keeping total calcium intake (diet plus supplements) at 1200 mg/day, not exceeding 2000 mg/day 16
• The Annals of Internal Medicine suggests that calcium supplementation resulted in one additional kidney stone for every 273 women treated over 7 years 17
• The Journal of the National Comprehensive Cancer Network recommends using conservative dosing: 1000 IU/day of vitamin D3, targeting serum 25-OH vitamin D levels of 30 ng/mL 18
• The combination of vitamin D (400 IU or less) plus calcium (1000 mg or less) increases kidney stone incidence with moderate certainty, according to the JAMA journal 17, 19

Monitoring and Prevention

• Measuring serum 25-OH vitamin D levels before supplementation decisions is recommended, according to the Journal of the National Comprehensive Cancer Network and the American Journal of Kidney Diseases 16, 18
• Monitoring 24-hour urinary calcium excretion before and 3 months after initiating vitamin D supplementation is advised, although the specific recommendation is not clearly cited 15

Management of Calcium‑Oxalate Nephrolithiasis in Patients Receiving Apixaban and Candesartan

Metabolic Evaluation

• Obtain two 24‑hour urine collections (≥ 6 weeks after any stone episode) measuring volume, pH, calcium, oxalate, uric acid, citrate, sodium, potassium, and creatinine to identify urinary abnormalities that guide targeted therapy. 20
• Perform stone composition analysis when stone material is available to confirm calcium‑oxalate composition. 21
• The combined metabolic work‑up (urine studies + stone analysis) enables detection of hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria, which direct specific dietary or pharmacologic interventions. 21

Fluid and General Dietary Measures

• Advise patients to increase fluid intake to ≈ 3 L/day (≈ 2–2.5 L urine output) to markedly lower recurrence risk; this volume should be individualized for body size and climate. 20
• Limit dietary sodium to ≤ 2,300 mg/day (≈ 100 mEq) because high sodium reduces renal tubular calcium reabsorption, raising urinary calcium excretion and stone risk. 20
• Reduce non‑dairy animal protein to 5–7 servings/week; animal‑protein metabolism generates sulfuric acid, which increases urinary calcium and uric acid excretion and decreases citrate, all promoting stone formation. 20

Targeted Pharmacologic Therapy

Potassium Citrate for Hypocitraturia

• Offer potassium citrate to patients with urinary citrate < 320 mg/day; typical dosing is 20 mEq three times daily (≈ 60 mEq/day), titrated to urine results.
• Potassium citrate raises urinary citrate by ~400 mg/day and urinary pH by ~0.7 units, inhibiting calcium‑oxalate crystallization. Evidence level: moderate (based on controlled studies). 21
• Monitor serum potassium before initiation and 1–2 weeks after starting, then periodically, because concomitant candesartan (an ARB) can increase potassium levels. 21

Thiazide Diuretics for Hypercalciuria

• Prescribe thiazide diuretics (hydrochlorothiazide 25–50 mg daily or chlorthalidone 25 mg daily) for patients with urinary calcium > 250 mg/day (women) or > 300 mg/day (men) and recurrent stones.
• Thiazides reduce stone recurrence (relative risk 0.52; 95 % CI 0.39–0.69), indicating a moderate‑to‑strong benefit. 21
• Monitor serum potassium (risk of hypokalemia) and fasting glucose (possible worsening of glucose control in metabolic‑syndrome/NAFLD patients). 21

Allopurinol for Hyperuricosuria

• Use allopurinol (200–300 mg/day) in patients with urinary uric acid > 800 mg/day and normal calcium excretion.
• Allopurinol lowers stone recurrence (relative risk 0.59; 95 % CI 0.42–0.84), providing moderate evidence of efficacy. 21
• Check liver enzymes periodically because allopurinol can cause hepatic elevation. 21

Drug‑Interaction Considerations

• Apixaban has no clinically significant interactions with thiazides, potassium citrate, or allopurinol; it can be continued without dose adjustment. 21
• Candesartan does not increase stone risk, but when combined with potassium citrate it raises the risk of hyperkalemia; therefore, serum potassium should be closely monitored. 21

Monitoring and Follow‑up

• Obtain a single 24‑hour urine specimen within 6 months of initiating therapy to assess response, then annual urine collections (or more frequently if stone activity persists). 21
• Perform periodic blood tests based on prescribed medications:
  
  • Serum potassium (especially with potassium citrate + candesartan) – 21
  • Serum glucose (if on thiazide) – 21
  • Liver enzymes and complete blood count (if on allopurinol) – 21
• Repeat stone composition analysis when treatment failure is suspected, as stone makeup may change over time. 21

Clinical Pitfalls

• Do not restrict dietary calcium; doing so increases urinary oxalate absorption and stone risk.
• Avoid using sodium citrate in place of potassium citrate, because the sodium load raises urinary calcium excretion.
• Recognize that passing a pre‑existing stone after dietary changes does not indicate treatment failure; differentiate stone passage from new stone formation. 20